INTERVIEW: Robert L. Coleman, MD, FACOG, FACS
TOPIC: Homologous Recombination Deﬁciency (HRD)
On February 20, 2023, Caris POA Chairman Dr. Chadi Nabhan sat down with Dr. Robert L. Coleman, Chief Scientific Officer at US Oncology Research, the research arm of The US Oncology Network. Together they discuss Homologous Recombination Deﬁciency (HRD) – why it’s important, what it means, therapy diagnostic implications, and an overview of the assay available at Caris Life Sciences.
Dr. Robert L. Coleman
Chief Scientific Officer
US Oncology Research
The US Oncology Network